These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11327200)

  • 1. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
    Olsson B; Szamosi J
    Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.
    Olsson B; Szamosi J
    Clin Pharmacokinet; 2001; 40(2):135-43. PubMed ID: 11286323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
    Malhotra B; Darsey E; Crownover P; Fang J; Glue P
    Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
    Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
    Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food increases the bioavailability of tolterodine but not effective exposure.
    Olsson B; Brynne N; Johansson C; Arnberg H
    J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
    Sathyan G; Dmochowski RR; Appell RA; Guo C; Gupta SK
    Clin Pharmacokinet; 2004; 43(14):1059-68. PubMed ID: 15530134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
    Simon HU; Malhotra B
    Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
    Dmochowski R; Chen A; Sathyan G; MacDiarmid S; Gidwani S; Gupta S
    J Clin Pharmacol; 2005 Aug; 45(8):961-8. PubMed ID: 16027408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities.
    Mahanta K; Medhi B; Kaur B; Narasimhan KL
    J Pediatr Urol; 2008 Apr; 4(2):118-23. PubMed ID: 18631906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
    Oishi M; Chiba K; Malhotra B; Suwa T
    Drug Metab Dispos; 2010 Sep; 38(9):1456-63. PubMed ID: 20530222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder.
    Kreder K; Mayne C; Jonas U
    Eur Urol; 2002 Jun; 41(6):588-95. PubMed ID: 12074774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
    Brynne N; Svanström C; Aberg-Wistedt A; Hallén B; Bertilsson L
    Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review.
    Rovner ES; Wein AJ
    Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.
    Ellsworth PI; Borgstein NG; Nijman RJ; Reddy PP
    J Urol; 2005 Oct; 174(4 Pt 2):1647-51; discussion 1651. PubMed ID: 16148673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
    Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
    Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.